Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus
Open Access
- 4 November 1998
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 280 (17), 1490-1496
- https://doi.org/10.1001/jama.280.17.1490
Abstract
Context.— Although the long-term health benefits of good glycemic control in patients with diabetes are well documented, shorter-term quality of life (QOL) and economic savings generally have been reported to be minimal or absent. Objective.— To examine short-term outcomes of glycemic control in type 2 diabetes mellitus (DM). Design.— Double-blind, randomized, placebo-controlled, parallel trial. Setting.— Sixty-two sites in the United States. Participants.— A total of 569 male and female volunteers with type 2 DM. Intervention.— After a 3-week, single-blind placebo-washout period, participants were randomized to diet and titration with either 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n=377) or placebo (n=192) for 12 weeks. Main Outcome Measures.— Change from baseline in glucose and hemoglobin A1c (HbA1c) levels and symptom distress, QOL, and health economic indicators by questionnaires and diaries. Results.— After 12 weeks, mean (±SE) HbA1c and fasting blood glucose levels decreased with active therapy (glipizide GITS) vs placebo (7.5%±0.1% vs 9.3%±0.1% and 7.0±0.1 mmol/L [126±2 mg/dL] vs 9.3±0.2 mmol/L [168±4 mg/dL], respectively; P<.001). Quality-of-life treatment differences (SD units) for symptom distress (+0.59; P<.001), general perceived health (+0.36; P=.004), cognitive functioning (+0.34; P=.005), and the overall visual analog scale (VAS) (+0.24; P=.04) were significantly more favorable for active therapy. Subscales of acuity (+0.38; P=.002), VAS emotional health (+0.35; P =.003), general health (+0.27; P =.01), sleep (+0.26; P =.04), depression (+0.25; P =.05), disorientation and detachment (+0.23; P =.05), and vitality (+0.22; P =.04) were most affected. Favorable health economic outcomes for glipizide GITS included higher retained employment (97% vs 85%; P<.001), greater productive capacity (99% vs 87%; P<.001), less absenteeism (losses=$24 vs $115 per worker per month; P <.001), fewer bed-days (losses=$1539 vs $1843 per 1000 person-days; P=.05), and fewer restricted-activity days (losses=$2660 vs $4275 per 1000 person-days; P=.01). Conclusions.— Improved glycemic control of type 2 DM is associated with substantial short-term symptomatic, QOL, and health economic benefits.Keywords
This publication has 7 references indexed in Scilit:
- Symptoms and Well-Being in Relation to Glycemic Control in Type II DiabetesDiabetes Care, 1996
- Cognitive function in patients with insulin-dependent diabetes mellitus during hyperglycemia and hypoglycemiaAmerican Journal Of Medicine, 1995
- Blood glucose estimation and symptoms during hyperglycemia and hypoglycemia in patients with insulin-dependent diabetes mellitusAmerican Journal Of Medicine, 1995
- The Relationship Between Glycemic Control and Health-Related Quality of Life in Patients With Non-Insulin-Dependent Diabetes MellitusMedical Care, 1994
- Comparative Measurement Sensitivity of Short and Longer Health Status InstrumentsMedical Care, 1992
- Symptom Perception and Blood Glucose Feedback in the Self-Treatment of IDDMPublished by Springer Science and Business Media LLC ,1990
- The Effects of Antihypertensive Therapy on the Quality of LifeNew England Journal of Medicine, 1986